LIXTE BIOTECHNOLOGY HOLDINGS, INC.
LIXT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for LIXT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LIXT
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) is a clinical-stage biopharmaceutical company focused on developing cancer therapies, primarily through inhibitors of protein phosphatase 2A, with its lead candidate LB-100 currently in clinical trials.
Key risk: Going concern uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$125.4M
Cash Runway
—
Lead Asset
lb-100 (Phase 1)
Next Catalyst
—
Tracking 1 pipeline candidate for LIXTE BIOTECHNOLOGY HOLDINGS, INC..
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) is a clinical-stage biopharmaceutical company focused on developing cancer therapies, primarily through inhibitors of protein phosphatase 2A, with its lead candidate LB-100 currently in clinical trials.
- LIXTE is a clinical-stage biopharmaceutical company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies [sec_mda · as of 2026-05-14].
- The company's product pipeline is primarily focused on inhibitors of protein phosphatase 2A, used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies [sec_mda · as of 2025-08-07].
- As of March 31, 2026, the company had cash of $3,250,650 available to fund its operations [sec_mda · as of 2026-05-14].
- The company has not generated recurring revenues since inception and has incurred negative operating cash flows as it advances its development programs [sec_mda · as of 2026-05-14].
- Management has concluded there is substantial doubt regarding the company's ability to continue as a going concern for at least 12 months beyond the filing of its quarterly report [sec_mda · as of 2026-05-14].
What works
- The company has a focused pipeline on protein phosphatase 2A inhibitors, which it believes have significant therapeutic potential for a broad range of cancers [sec_mda · as of 2025-08-07].
- The company operates with a minimum of overhead, moving compounds forward as efficiently and inexpensively as possible, and raises funds as milestones are reached [sec_mda · as of 2025-11-12].
- The company's longer-term objective is to secure strategic partnerships or licensing agreements with pharmaceutical companies with major programs in cancer [sec_mda · as of 2025-11-12].
What to weigh
- The company has not generated recurring revenues since inception and has incurred negative operating cash flows [sec_mda · as of 2026-05-14].
- As of March 31, 2026, the company had only $3,250,650 in cash, and management has expressed substantial doubt about its ability to continue as a going concern [sec_mda · as of 2026-05-14].
- Existing cash resources are not sufficient to complete the development of and obtain regulatory approval for its product candidate, which would require significant additional operating capital [sec_mda · as of 2025-11-12].
- There is a risk that clinical trials for LB-100 could be placed on hold by regulatory authorities due to serious adverse events [sec_mda · as of 2025-11-12].
From the filings
Quoted directly from source documents.
The company is a clinical-stage biopharmaceutical company focused on cancer therapies.
“The Company is a clinical-stage biopharmaceutical company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies.”
SEC MD&A · May 14, 2026
The company's cash position as of March 31, 2026.
“of March 31, 2026, the Company had cash of $3,250,650 available to fund its operations.”
SEC MD&A · May 14, 2026
Substantial doubt about going concern.
“management has concluded that there is a substantial doubt regarding the Company's ability to continue as a going concern for a period of at least 12 months beyond the filing of this quarterly report.”
SEC MD&A · May 14, 2026
The company's lead product candidate is LB-100.
“the development of the Company's lead anti-cancer clinical compound LB-100”
SEC MD&A · November 12, 2025
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Management has concluded substantial doubt exists about the company's ability to continue as a going concern for at least 12 months [sec_mda · as of 2026-05-14].
- Insufficient cash for development — Existing cash resources are not sufficient to complete development and obtain regulatory approval for LB-100 [sec_mda · as of 2025-11-12].
- Clinical trial hold risk — There is a risk that clinical trials for LB-100 could be placed on hold by regulatory authorities due to serious adverse events [sec_mda · as of 2025-11-12].
- No recurring revenues — The company has not generated recurring revenues since inception and has incurred negative operating cash flows [sec_mda · as of 2026-05-14].
What to watch
- Ability to raise additional equity capital to fund research and development activities, including ongoing clinical trials [sec_mda · as of 2025-11-12].
- Progress and results of clinical trials for lead product candidate LB-100 [sec_mda · as of 2026-03-31].
- Potential strategic partnerships or licensing agreements with pharmaceutical companies [sec_mda · as of 2025-11-12].
- Regulatory developments, including any clinical holds due to serious adverse events [sec_mda · as of 2025-11-12].
Sources: SEC MD&A · Generated August 11, 2026 · How we verify sources →
Run LIXTE BIOTECHNOLOGY HOLDINGS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available LIXTE BIOTECHNOLOGY HOLDINGS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Governance
Frequently asked questions
What is the AI investment thesis for LIXTE BIOTECHNOLOGY HOLDINGS, INC.?
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) is a clinical-stage biopharmaceutical company focused on developing cancer therapies, primarily through inhibitors of protein phosphatase 2A, with its lead candidate LB-100 currently in clinical trials.
What is LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s lead drug candidate?
LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s most advanced tracked candidate is lb-100 (Phase 1) for Advanced Soft Tissue Sarcoma.
Who is the CEO of LIXTE BIOTECHNOLOGY HOLDINGS, INC.?
Mr. John Francis Travaglini is the chief executive officer of LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT).
Where is LIXTE BIOTECHNOLOGY HOLDINGS, INC. headquartered?
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) is headquartered in Waterbury, VT, United States.
What therapeutic areas does LIXTE BIOTECHNOLOGY HOLDINGS, INC. focus on?
LIXTE BIOTECHNOLOGY HOLDINGS, INC. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.